Autologous CRISPR-Cas9 Engineered Regnase-1/SOCS1 Dual-edited Tumor Infiltrating Lymphocytes KSQ-004EX

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous tumor infiltrating lymphocytes (TILs) gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to inactivate both the endogenous genes suppressor of cytokine signaling 1 (SOCS1) and Regnase-1, with potential immunomodulating and antineoplastic activities. Upon infusion of the autologous CRISPR-Cas9 engineered Regnase-1/SOCS1 dual-edited TILs KSQ-004EX back into the patient, the cells specifically recognize, target and kill the patient's tumor cells. Inactivation of endogenous SOCS1 and Regnase-1 in the TILs increases responsiveness to cytokine signals, increases persistence and memory formation of TILs, and enhances anti-tumor responses.

**Synonyms:** - Autologous CRISPR-Cas9 Engineered TILs KSQ-004EX - Autologous Dual-edit eTILs KSQ-004EX - Autologous Engineered Tumor Infiltrating Lymphocytes KSQ-004EX - Autologous SOCS1/Regnase-1 Inactivated Engineered TILs KSQ-004EX - Autologous SOCS1/Regnase-1-edited TILs KSQ-004EX - Autologous eTILs KSQ-004EX - CRISPR/Cas9-edited SOCS1/Regnase-1 Gene-inactivated Autologous TILs KSQ-004EX - KSQ 004 - KSQ 004EX - KSQ-004 - KSQ-004EX - KSQ004 - KSQ004EX - Regnase-1/SOCS1 Dual-edited Human CRISPR/Cas9-engineered TILs KSQ-004EX